JP2013507991A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507991A5
JP2013507991A5 JP2012536968A JP2012536968A JP2013507991A5 JP 2013507991 A5 JP2013507991 A5 JP 2013507991A5 JP 2012536968 A JP2012536968 A JP 2012536968A JP 2012536968 A JP2012536968 A JP 2012536968A JP 2013507991 A5 JP2013507991 A5 JP 2013507991A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
amino acid
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012536968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507991A (ja
JP5930968B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/054148 external-priority patent/WO2011056600A1/en
Publication of JP2013507991A publication Critical patent/JP2013507991A/ja
Publication of JP2013507991A5 publication Critical patent/JP2013507991A5/ja
Application granted granted Critical
Publication of JP5930968B2 publication Critical patent/JP5930968B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012536968A 2009-10-26 2010-10-26 ヒトil−23抗原結合タンパク質 Active JP5930968B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25498209P 2009-10-26 2009-10-26
US61/254,982 2009-10-26
US38128710P 2010-09-09 2010-09-09
US61/381,287 2010-09-09
PCT/US2010/054148 WO2011056600A1 (en) 2009-10-26 2010-10-26 Human il-23 antigen binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015236268A Division JP2016102122A (ja) 2009-10-26 2015-12-03 ヒトil−23抗原結合タンパク質

Publications (3)

Publication Number Publication Date
JP2013507991A JP2013507991A (ja) 2013-03-07
JP2013507991A5 true JP2013507991A5 (enExample) 2013-12-05
JP5930968B2 JP5930968B2 (ja) 2016-06-08

Family

ID=43413789

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012536968A Active JP5930968B2 (ja) 2009-10-26 2010-10-26 ヒトil−23抗原結合タンパク質
JP2015236268A Pending JP2016102122A (ja) 2009-10-26 2015-12-03 ヒトil−23抗原結合タンパク質
JP2018045121A Pending JP2018117626A (ja) 2009-10-26 2018-03-13 ヒトil−23抗原結合タンパク質
JP2019166277A Active JP7023908B2 (ja) 2009-10-26 2019-09-12 ヒトil-23抗原結合タンパク質
JP2021177428A Active JP7278355B2 (ja) 2009-10-26 2021-10-29 ヒトil-23抗原結合タンパク質

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015236268A Pending JP2016102122A (ja) 2009-10-26 2015-12-03 ヒトil−23抗原結合タンパク質
JP2018045121A Pending JP2018117626A (ja) 2009-10-26 2018-03-13 ヒトil−23抗原結合タンパク質
JP2019166277A Active JP7023908B2 (ja) 2009-10-26 2019-09-12 ヒトil-23抗原結合タンパク質
JP2021177428A Active JP7278355B2 (ja) 2009-10-26 2021-10-29 ヒトil-23抗原結合タンパク質

Country Status (39)

Country Link
US (9) US8722033B2 (enExample)
EP (3) EP2493925B1 (enExample)
JP (5) JP5930968B2 (enExample)
KR (3) KR101652609B1 (enExample)
CN (3) CN102741285B (enExample)
AR (1) AR078778A1 (enExample)
AU (1) AU2010315557B2 (enExample)
BR (2) BR112012009854B8 (enExample)
CA (2) CA2778112C (enExample)
CL (1) CL2012001096A1 (enExample)
CO (1) CO6531481A2 (enExample)
CR (1) CR20120210A (enExample)
CY (1) CY1118576T1 (enExample)
EA (1) EA025366B1 (enExample)
ES (1) ES2613236T3 (enExample)
HK (1) HK1212357A1 (enExample)
HR (1) HRP20170037T1 (enExample)
HU (1) HUE030871T2 (enExample)
IL (3) IL219241A (enExample)
JO (1) JO3244B1 (enExample)
LT (1) LT2493925T (enExample)
MA (1) MA33757B1 (enExample)
MX (1) MX358249B (enExample)
MY (1) MY156286A (enExample)
NZ (2) NZ599875A (enExample)
PE (2) PE20121579A1 (enExample)
PH (1) PH12012500771A1 (enExample)
PL (1) PL2493925T3 (enExample)
PT (1) PT2493925T (enExample)
RS (1) RS55666B1 (enExample)
SG (2) SG10202103260TA (enExample)
SI (1) SI2493925T1 (enExample)
SM (1) SMT201700069T1 (enExample)
TN (1) TN2012000167A1 (enExample)
TW (2) TW201417830A (enExample)
UA (1) UA113609C2 (enExample)
UY (1) UY32971A (enExample)
WO (1) WO2011056600A1 (enExample)
ZA (1) ZA201203058B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
US9012161B2 (en) * 2011-01-25 2015-04-21 Monell Chemical Senses Center Methods of identifying molecules that provide or enhance sweet taste
EP2583979B1 (en) * 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
KR102124758B1 (ko) * 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-il-23p19 항체
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
CN105307675A (zh) * 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
HK1219425A1 (zh) * 2013-03-15 2017-04-07 Amgen Inc. 使用抗il-23抗体治疗银屑病的方法
EP3808857B1 (en) 2013-10-21 2025-12-10 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
ES2873204T3 (es) 2013-10-21 2021-11-03 Takeda Pharmaceuticals Co Diagnóstico y tratamiento de enfermedades autoinmunes
WO2015160858A2 (en) 2014-04-15 2015-10-22 Sorrento Therapeutics, Inc. Antigen binding proteins that bind wisp1
EP4198059A1 (en) 2014-05-27 2023-06-21 The University of Queensland Modulation of cellular stress
US20170198059A1 (en) 2014-07-14 2017-07-13 Amgen Inc. Crystalline antibody formulations
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
SG11201705728RA (en) 2015-02-04 2017-08-30 Boehringer Ingelheim Int Methods of treating inflammatory diseases
JP6909208B2 (ja) 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
EP4354146A3 (en) * 2015-10-19 2024-06-05 Takeda Pharmaceutical Company Limited Immunoassay for the detection of cleaved high molecular weight kininogen
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
EP3661968B1 (en) * 2017-08-04 2022-03-02 The Hospital for Sick Children Nanoparticle platform for antibody and vaccine delivery
WO2019023812A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children VACCINE COMPOSITION AGAINST MALARIA AND METHOD THEREOF
TWI837532B (zh) 2018-03-30 2024-04-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
EA202190197A1 (ru) 2018-07-13 2021-04-26 Астразенека Коллаборэйшн Венчерз, Ллс Лечение язвенного колита с помощью бразикумаба
GB201820687D0 (en) * 2018-12-19 2019-01-30 Kymab Ltd Antagonists
JP2022536088A (ja) * 2019-06-04 2022-08-12 ヤンセン バイオテツク,インコーポレーテツド 抗il23特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
US11725058B2 (en) * 2019-06-26 2023-08-15 Ap Biosciences, Inc. CD137 antibodies for T-cell activation
CN115135671A (zh) 2019-12-20 2022-09-30 新石生物制药有限公司 抗白介素-23 p19的抗体及其使用方法
CN111718414B (zh) * 2020-06-12 2021-03-02 江苏荃信生物医药有限公司 抗人白介素23单克隆抗体及其应用
WO2022041390A1 (zh) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
AR123477A1 (es) 2020-09-10 2022-12-07 Lilly Co Eli Formulaciones de anticuerpos terapéuticos
CN112625129B (zh) * 2020-11-26 2022-05-20 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法
US20220373539A1 (en) * 2021-05-24 2022-11-24 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
CA3222871A1 (en) * 2021-06-25 2022-12-29 Sangamo Therapeutics, Inc. Antigen binders specific for il-23r and uses thereof
WO2023056417A1 (en) 2021-09-30 2023-04-06 Eli Lilly And Company Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
CN114994331B (zh) * 2022-05-17 2023-02-24 无锡科金生物科技有限公司 一种检测蛋白表达水平的试剂盒及其制备方法和应用
WO2024077113A1 (en) 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
AU2249592A (en) 1991-06-14 1993-01-12 Dnx Corporation Production of human hemoglobin in transgenic pigs
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
SG47979A1 (en) 1991-11-14 1998-04-17 Charles Weissman Transgenic animals lacking prion proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
EP0672141B1 (en) 1992-10-23 2003-05-14 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ES2299241T3 (es) 1998-03-17 2008-05-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para enfermedades intestinales inflamatorias que contienen anticuerpos antagonistas del receptor il-6.
EP1072610B1 (en) 1998-04-14 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Novel cytokine-like protein
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
ES2300276T5 (es) 1999-09-09 2017-06-02 Merck Sharp & Dohme Corp. P40 de interleuquina-12 de mamífero e interleuquina B30. Sus combinaciones. Anticuerpos. Usos en composiciones farmacéuticas
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
WO2004042009A2 (en) 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
CA2506672C (en) 2002-12-23 2012-04-17 Schering Corporation Il-23 for treating cutaneous wounds
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
TWI439285B (zh) 2003-03-10 2014-06-01 Merck Sharp & Dohme Il-23激動劑及拮抗劑之用途及相關試劑
AU2004239288B2 (en) 2003-05-09 2010-01-28 Centocor, Inc. IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
CN1993480A (zh) 2004-05-03 2007-07-04 先灵公司 Il-17表达预测皮肤炎症的用途;治疗方法
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
WO2006068987A2 (en) 2004-12-20 2006-06-29 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
JP2008523842A (ja) 2004-12-21 2008-07-10 セントカー・インコーポレーテツド 抗il−12抗体、エピトープ、組成物、方法および用途
PT1896073E (pt) 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
BRPI0611714A2 (pt) 2005-06-30 2009-01-13 Abbott Lab proteÍnas de ligaÇço a il-12/p40
ES2347690T3 (es) 2005-08-25 2010-11-03 Eli Lilly And Company Anticuerpos anti-il-23.
ME02705B (me) * 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
CN1955248B (zh) * 2005-10-28 2011-10-12 安集微电子(上海)有限公司 钽阻挡层用化学机械抛光浆料
AU2006330410A1 (en) 2005-12-28 2007-07-05 Centocor, Inc. Markers and methods for assessing and treating psoriasis and related disorders
PT2548577T (pt) 2005-12-29 2017-05-29 Janssen Biotech Inc Anticorpos humanos anti-il-23, composições, métodos e usos
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス, インコーポレイテッド Il−17およびil−23アンタゴニストならびにその使用方法
CA2675233A1 (en) * 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
SI2426144T1 (sl) 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
CN101663320A (zh) 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
CA2706200A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs comprising multiple single variable domains and an fc portion
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
TWI461210B (zh) 2008-03-18 2014-11-21 Abbvie Inc 治療牛皮癬的方法
US8557239B2 (en) * 2009-09-14 2013-10-15 Abbvie Inc. Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
UA104297C2 (en) 2008-08-14 2014-01-27 Сефалон Острейлиа Пти Лтд Anti-il-12/il-23 antibody
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
EP2414393A1 (en) 2009-04-01 2012-02-08 Glaxo Group Limited Anti-il-23 immunoglobulins
US20120027799A1 (en) 2009-04-02 2012-02-02 The Johns Hopkins University Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
WO2010142534A1 (en) 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2523688B1 (en) 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
US8927693B2 (en) 2010-02-18 2015-01-06 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
EP2596022A4 (en) 2010-07-20 2014-11-05 Cephalon Australia Pty Ltd SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23
WO2012048134A2 (en) 2010-10-06 2012-04-12 Abbott Laboratories Methods for treating psoriasis
JP5537740B2 (ja) 2010-10-08 2014-07-02 ノバルティス アーゲー Il−17アンタゴニストを用いて乾癬を治療する方法
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
EP2661448A4 (en) 2011-01-07 2015-09-16 Abbvie Inc ANTI-IL-12 / IL-23 ANTIBODIES AND USES THEREOF
CN105307675A (zh) 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
JP6909208B2 (ja) 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測
AU2016379157A1 (en) 2015-12-22 2018-06-21 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
EA202190197A1 (ru) 2018-07-13 2021-04-26 Астразенека Коллаборэйшн Венчерз, Ллс Лечение язвенного колита с помощью бразикумаба
KR20220045039A (ko) 2019-08-21 2022-04-12 아스트라제네카 콜라보레이션 벤처스, 엘엘씨 크론병 치료를 위한 브라지쿠맙의 용도

Similar Documents

Publication Publication Date Title
JP2013507991A5 (enExample)
PH12021500002A1 (en) ANTIBODY-SIRPa ANTIBODY
JP2012504955A5 (enExample)
JP2015508762A5 (enExample)
CN104774266B (zh) 白介素-13结合蛋白
JP2019536442A5 (enExample)
JP2014524748A5 (enExample)
JP2020508303A5 (enExample)
JP2018505177A5 (enExample)
JP2019522961A5 (enExample)
JP2018521638A5 (enExample)
JP2017528476A5 (enExample)
JP2015522252A5 (enExample)
JP2011514150A5 (enExample)
JP2020536888A5 (enExample)
JP2018064580A5 (enExample)
JP2009511480A5 (enExample)
JP2012513214A5 (enExample)
JP2018527952A5 (enExample)
RU2013110874A (ru) Антитела против il-18r1 и их применения
JP2011528902A5 (enExample)
JP2019536806A5 (enExample)
NZ603488A (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
JP2020506900A5 (enExample)
JP2015501149A5 (enExample)